Fig. 4

circ_0072083 targets miR-1252-5p to regulate ALKBH5/NANOG and TMZ resistance in the resistant glioma cells. a The potential miRNA that interacted with circ_0072083, ALKBH5 and NANOG was analyzed via Circinteractome and starBase. b The binding site of miR-1252-5p and circ_0072083, ALKBH5 and NANOG was exhibited. c miR-1252-5p expression were detected via qRT-PCR in TMZ-resistant (n = 36) or sensitive tissues (n = 33). d miR-1252-5p abundance was measured by qRT-PCR in TME-resistant and sensitive cells. e-g Luciferase activity was detected in 293 T cells with transfection of miR-1252-5p mimic or miR-NC and the constructed luciferase reporter vectors. h miR-1252-5p, circ_0072083, ALKBH5 and NANOG levels were detected after RIP assay using anti-Ago2 or anti-IgG. i miR-1252-5p expression was measured via qRT-PCR in cells transfected with sh-circ or sh-NC. (J and K) ALKBH5 and NANOG levels were detected via qRT-PCR and western blot in cells transfected with miR-1252-5p mimic or miR-NC. l miR-1252-5p expression was measured via qRT-PCR in cells transfected with anti-miR-1252-5p or anti-NC. m and n ALKBH5 and NANOG levels were examined via qRT-PCR and western blot in cells transfected with sh-NC + anti-NC, sh-circ_0072083 + anti-NC or sh-circ_0072083 + anti-miR-1252-5p. IC50 of TMZ o, cell proliferation p, colony ability q, apoptosis r, migration s and t and invasion u were measured by CCK-8, colony formation, flow cytometry, wound healing and transwell analyses respectively in resistant cells transfected with sh-NC + anti-NC, sh-circ_0072083 + anti-NC or sh-circ_0072083 + anti-miR-1252-5p after treatment of the indicated concentration of TMZ. ^*P < 0.05